Clinical utility gene card for: Malignant hyperthermia

European Journal of Human Genetics

Volumn 19, Issue 6, 2011, Pages

  Rosenberg, Henry ^a   Rueffert, Henrik ^b,c  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c HELIOS Kliniken Leipziger Land   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLUE CONE MONOCHROMATISM; CLINICAL UTILITY GENE CARD; COLOR BLINDNESS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ETHNIC GROUP; GENE CLUSTER; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; AGE; ARTICLE; BIOPSY; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; GENE FREQUENCY; GENETICS; INCIDENCE; MALIGNANT HYPERTHERMIA; MUTATION; MYOPATHY; NEUROLEPTIC MALIGNANT SYNDROME; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION MAPPING;

CACNA1S PROTEIN, HUMAN; CALCIUM CHANNEL; DANTROLENE; RYANODINE RECEPTOR;

AGE FACTORS; BIOPSY; CALCIUM CHANNELS; DANTROLENE; DIAGNOSIS, DIFFERENTIAL; GENE FREQUENCY; HUMANS; INCIDENCE; MALIGNANT HYPERTHERMIA; MUTATION; MYOPATHIES, STRUCTURAL, CONGENITAL; NEUROLEPTIC MALIGNANT SYNDROME; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREDICTIVE VALUE OF TESTS; RESTRICTION MAPPING; RISK FACTORS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SEQUENCE ANALYSIS, DNA;

EID: 79956323637     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2010.248     Document Type: Short Survey

References (29)

1. European Malignant Hyperthermia Group (EMHG), http://www.emhg.org.
2. Malignant Hyperthermia Association of the United States (MHAUS), http://www. mhaus.org.
3. McCarthy TV, Healy JM, Heffron JJ et al: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-564.
4. Monnier N, Procaccio V, Stieglitz P, Lunardi J: Malignant-hyperthermia susceptibility is associated with a mutation of the alpha-1-subunit of the human dihydropyridinesensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316-1325. (Pubitemid 27258063)
5. Urwyler A, Deufel T, McCarthy T, West S: Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-287. (Pubitemid 32103424)
6. McCarthy TV, Quane KA, Lynch PJ: Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-417. (Pubitemid 30331213)
7. Sambuughin N, Holley H, Muldoon S et al: Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology 2005; 102: 515-521. (Pubitemid 40315139)
8. Stewart SL, Hogan K, Rosenberg H, Fletcher JE: Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001; 59: 178-184. (Pubitemid 32229773)
9. Ibarra MC, Wu S, Murayama K et al: Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006; 104: 1146-1154. (Pubitemid 43852946)
10. Rueffert H, Olthoff D, Deutrich C et al: Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations. Acta Anaesthesiol Scand 2002; 46: 692-698. (Pubitemid 34628043)
11. Levano S, Vukcevic M, Singer M et al: Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009; 30: 590-598.
12. Girard T, Litman RS: Molecular genetic testing to diagnose malignant hyperthermia susceptibility. J Clin Anesth 2008; 20: 161-163. (Pubitemid 351698115)
13. Stowell KM, Pollock N: DNA analysis and malignant hyperthermia susceptibility. Anaesth Intensive Care 2008; 36: 305-307.
14. Monnier N, Krivosic-Horber R, Payen JF et al: Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97: 1067-1074. (Pubitemid 35265557)
15. Ording H: Incidence of malignant hyperthermia in Denmark. Anesth Analg 1985; 64: 700-704. (Pubitemid 15064913)
16. Brady JE, Sun LS, Rosenberg H, Li G: Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg 2009; 109: 1162-1166.
17. Ording H, Brancadoro V, Cozzolino S et al: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-966.
18. Larach MG, Localio AR, Allen GC et al: A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779. (Pubitemid 24128939)
19. Wappler F: Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol 2010; 23: 417-422.
20. Rosenberg H, Davis M, James D et al: Malignant hyperthermia. Orphanet J Rare Dis 2007; 2: 21.
21. Litman RS, Rosenberg H: Malignant hyperthermia: update on susceptibility testing. JAMA 2005; 293: 2918-2924. (Pubitemid 41029146)
22. Zhou H, Lillis S, Loy RE et al: Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2010; 20: 166-173.
23. Wilmshurst JM, Lillis S, Zhou H et al: RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 2010; 68: 717-726.
24. Treves S, Jungbluth H, Muntoni F, Zorzato F: Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 2008; 8: 319-326.
25. Robinson RL, Brooks C, Brown SL et al: RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 2002; 20: 88-97. (Pubitemid 34810064)
26. Carpenter D, Robinson RL, Quinnell RJ et al: Genetic variation in RYR1and malignant hyperthermia phenotypes. Br J Anaesth 2009; 103: 538-548.
27. Ducreux S, Zorzato F, Ferreiro A et al: Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multiminicore disease and central core disease, expressed in immortalized lymphocytes. Biochem J 2006; 395: 259-266.
28. Larach MG: Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989; 69: 511-515.
29. Rosenberg H, Dirksen RA, Sambuughin N: Malignant hyperthermia susceptibility; in Baskin P, Pagan R (ed): GeneReviews, http://www.genetests. org.